EE733 Transfusion-Related Cost and Time Burden in JAKi-Naïve and JAKi-Experienced Patients With Myelofibrosis Treated With Momelotinib and Ruxolitinib From the SIMPLIFY 1 and 2 Studies: A Brazilian Supplementary Health Perspective